US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Faeth Therapeutics

33.39

+1.394.34%

Volume:72.25K

Turnover:2.35M

Market Cap:860.75M

PE:-0.24

High:34.17

Open:32.80

Low:30.30

Close:32.00

52wk High:37.90

52wk Low:7.45

Shares:25.78M

Float Shares:811.70K

Volume Ratio:0.59

T/O Rate:8.90%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-141.6499

EPS(LYR):-16.7239

ROE:-195.26%

ROA:-20.79%

PB:4.98

PE(LYR):-2.00

Loading ...

Overview Company News Filings

Sensei Biotherapeutics director Stephen M. Hahn files initial beneficial ownership statement

Sensei Biotherapeutics Price Target Maintained With a $55.00/Share by BTIG

Sensei Biotherapeutics changes name to Faeth Therapeutics, adopts ticker FTH

Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing Piktor, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer

THOMSON REUTERS

Sensei Biotherapeutics - Appoints Anand Parikh as Chairman, President and CEO Effective June 12, 2026

THOMSON REUTERS

Sensei Biotherapeutics - Piktor Phase 1B/2 Interim Data in Hr+/Her2- Advanced Breast Cancer Expected in 2027

THOMSON REUTERS

Sensei Biotherapeutics - Appoints Brian Stephenson as Chief Financial Officer

THOMSON REUTERS

Sensei Biotherapeutics - Common Stock to Begin Trading as Fth on Nasdaq on June 16, 2026

THOMSON REUTERS

Sensei Biotherapeutics - Piktor Phase 2 Topline Data in Advanced Endometrial Cancer Expected Second Half 2026

THOMSON REUTERS

Press Release: Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer

Sensei Biotherapeutics Inc : Btig Initiates Coverage With Buy Rating; Target Price $55

THOMSON REUTERS

Sensei Biotherapeutics initiated with a Buy at BTIG

Sensei Biotherapeutics Initiated at Buy by BTIG

Sensei Biotherapeutics Overhauls Capital Structure at 2026 Meeting

Sensei Biotherapeutics shareholders approve increase in authorized common shares to 300,000,000

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/FTH/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"FTH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FTH\",,,,,undefined,":{"symbol":"FTH","market":"US","secType":"STK","nameCN":"Faeth Therapeutics","latestPrice":33.39,"timestamp":1787586327009,"preClose":32,"halted":0,"volume":72250,"delay":0,"changeRate":0.04343750000000002,"floatShares":811700,"shares":25778800,"eps":-141.6499,"marketStatus":"Trading","change":1.39,"latestTime":"08-24 11:46:01 EDT","open":32.8,"high":34.17,"low":30.3,"amount":2346657.6025,"amplitude":0.120938,"askPrice":33.64,"askSize":210,"bidPrice":33.38,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-141.6499,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787601600000},"marketStatusCode":2,"adr":0,"listingDate":1612414800000,"exchange":"NASDAQ","adjPreClose":32,"preHourTrading":{"tag":"盘前","latestPrice":32,"preClose":32,"latestTime":"07:02 EDT","volume":5,"amount":160,"timestamp":1787569349699,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":32,"preClose":32,"latestTime":"19:30 EDT","volume":1722,"amount":55104,"timestamp":1787355006301,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.589257},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FTH\",,,,,undefined,":{"symbol":"FTH","floatShares":811700,"roa":"-20.79%","roe":"-195.26%","lyrEps":-16.72388,"volumeRatio":0.589257,"shares":25778800,"dividePrice":0,"high":34.17,"amplitude":0.120938,"preClose":32,"low":30.3,"week52Low":7.45,"pbRate":"4.98","week52High":37.9,"institutionHeld":0,"latestPrice":33.39,"committee":-0.02439,"eps":-141.6499,"divideRate":0,"volume":72250,"delay":0,"ttmEps":-141.6499,"open":32.8,"prevYearClose":10.67,"prevWeekClose":32,"prevMonthClose":27.24,"prevQuarterClose":25,"fiveDayClose":32.77,"twentyDayClose":29.24,"sixtyDayClose":17.59},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FTH\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-04","symbol":"FTH","fiscalQuarterEnding":"2026/06","expectedEps":-1.1,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785816000000,"reportTimeType":"pre","actualEps":-2.84},{"market":"US","date":"2026-05-15","symbol":"FTH","fiscalQuarterEnding":"2026/03","expectedEps":-0.62,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"pre","actualEps":-131.45},{"market":"US","date":"2026-03-30","symbol":"FTH","fiscalQuarterEnding":"2025/12","expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774843200000,"reportTimeType":"pre","actualEps":-3.74},{"market":"US","date":"2025-11-14","symbol":"FTH","fiscalQuarterEnding":"2025/09","expectedEps":-4.11,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"pre","actualEps":-3.62},{"market":"US","date":"2025-08-05","symbol":"FTH","fiscalQuarterEnding":"2025/06","expectedEps":-6.2,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1754366400000,"reportTimeType":"pre","actualEps":-3.91}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FTH\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FTH\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4167,"buy":0.5833,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5833,"analysts":12,"updateTime":1785902400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/FTH\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"FTH","date":"2026-08-21","current":-0.232803,"percent":0.204545,"low":-5.053534,"twenty":-4.248589,"median":-3.806921,"eighty":-3.244483,"high":-0.105707,"avg":-3.520013,"sd":1.147061,"marketCap":829477642},"quantilePoints":[{"date":"2026-06-18","current":-0.12113,"twenty":-0.118045,"median":-0.113419,"eighty":-0.108792,"marketCap":22343317},{"date":"2026-06-26","current":-3.447751,"twenty":-3.41449,"median":-0.168709,"eighty":-0.122832,"marketCap":635961861},{"date":"2026-07-02","current":-3.306599,"twenty":-3.429583,"median":-3.245107,"eighty":-0.129642,"marketCap":609925319},{"date":"2026-07-10","current":-4.547622,"twenty":-3.49387,"median":-3.330357,"eighty":-0.168709,"marketCap":838840655},{"date":"2026-07-17","current":-3.62524,"twenty":-4.398084,"median":-3.429583,"eighty":-3.196193,"marketCap":668700878},{"date":"2026-07-24","current":-3.879594,"twenty":-4.005373,"median":-3.554664,"eighty":-3.20318,"marketCap":715618211},{"date":"2026-07-31","current":-4.027734,"twenty":-4.074133,"median":-3.637119,"eighty":-3.236722,"marketCap":742943690},{"date":"2026-08-07","current":-3.227486,"twenty":-4.048697,"median":-3.62524,"eighty":-3.239088,"marketCap":631063897},{"date":"2026-08-14","current":-3.773087,"twenty":-4.030809,"median":-3.711043,"eighty":-3.239088,"marketCap":737744133},{"date":"2026-08-21","current":-4.242245,"twenty":-4.248589,"median":-3.806921,"eighty":-3.244483,"marketCap":829477642}],"updateTime":1787545070751},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FTH\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2644603587","title":"Sensei Biotherapeutics director Stephen M. Hahn files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2644603587","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644603587?lang=en_us&edition=fundamental","pubTime":"2026-06-17 04:19","pubTimestamp":1781641173,"startTime":"0","endTime":"0","summary":"Sensei Biotherapeutics director Stephen M. Hahn reported holding 44,763 shares underlying Series B Preferred Stock in an initial Form 3 filing dated June 12, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sensei Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 16, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDLfkvCs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNSE","FTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643279207","title":"Sensei Biotherapeutics Price Target Maintained With a $55.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2643279207","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643279207?lang=en_us&edition=fundamental","pubTime":"2026-06-16 01:12","pubTimestamp":1781543520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SNSE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 15, 2026 13:12 ET (17:12 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FTH","SNSE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643203988","title":"Sensei Biotherapeutics changes name to Faeth Therapeutics, adopts ticker FTH","url":"https://stock-news.laohu8.com/highlight/detail?id=2643203988","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643203988?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:10","pubTimestamp":1781525416,"startTime":"0","endTime":"0","summary":"Sensei Biotherapeutics rebranded as Faeth Therapeutics, pivoting to PIKTOR, an oral multi-node inhibitor of the PI3K/AKT/mTOR pathway.Common stock expected to trade on Nasdaq under ticker FTH on June 16, 2026.Company cited $200 million in gross proceeds from a private placement tied to its February 2026 Faeth acquisition.PIKTOR Phase 2 topline data in advanced endometrial cancer targeted for the second half of 2026; breast cancer interim data expected in 2027.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDLb5lBPr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FTH","BK4139","SNSE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643920350","title":"Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing Piktor, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2643920350","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643920350?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:10","pubTimestamp":1781525400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA7ZVHXH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNSE","BK4139","FTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643605203","title":"Sensei Biotherapeutics - Appoints Anand Parikh as Chairman, President and CEO Effective June 12, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2643605203","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643605203?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:10","pubTimestamp":1781525400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA7ZVHXH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FTH","SNSE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643203953","title":"Sensei Biotherapeutics - Piktor Phase 1B/2 Interim Data in Hr+/Her2- Advanced Breast Cancer Expected in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2643203953","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643203953?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:10","pubTimestamp":1781525400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA7ZVHXH:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FTH","SNSE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643203677","title":"Sensei Biotherapeutics - Appoints Brian Stephenson as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2643203677","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643203677?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:10","pubTimestamp":1781525400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA7ZVHXH:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FTH","SNSE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643203603","title":"Sensei Biotherapeutics - Common Stock to Begin Trading as Fth on Nasdaq on June 16, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2643203603","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643203603?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:10","pubTimestamp":1781525400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA7ZVHXH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FTH","BK4139","SNSE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643039582","title":"Sensei Biotherapeutics - Piktor Phase 2 Topline Data in Advanced Endometrial Cancer Expected Second Half 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2643039582","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643039582?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:10","pubTimestamp":1781525400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA7ZVHXH:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNSE","BK4139","FTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643203959","title":"Press Release: Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2643203959","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643203959?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:10","pubTimestamp":1781525400,"startTime":"0","endTime":"0","summary":"-- Stockholders approved conversion of the Series B preferred stock issued in the February 2026 acquisition of Faeth Therapeutics and concurrent private placement --. -- Company changed name to Faeth Therapeutics, Inc. on June 15, 2026; common stock expected to begin trading under the ticker symbol \"FTH\" on June 16, 2026 --. -- Anand Parikh, Faeth co-founder, appointed Chairman, President and Chief Executive Officer; Brian Stephenson, Ph.D., CFA appointed Chief Financial Officer; board strengthened with the addition of former FDA Commissioner Stephen M. Hahn, M.D., and Saira Ramasastry --. -- PIKTOR, an investigational all-oral multi-node inhibitor of the PI3K/AKT/mTOR pathway, on track for topline Phase 2 data in advanced endometrial cancer in the second half of 2026 --. Effective June 12, 2026, the Company appointed a new executive leadership team. Anand Parikh, a","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FTH","BK4139","SNSE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642285292","title":"Sensei Biotherapeutics Inc : Btig Initiates Coverage With Buy Rating; Target Price $55","url":"https://stock-news.laohu8.com/highlight/detail?id=2642285292","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642285292?lang=en_us&edition=fundamental","pubTime":"2026-06-11 18:37","pubTimestamp":1781174252,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nFWN42J0P1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNSE","FTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642850672","title":"Sensei Biotherapeutics initiated with a Buy at BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2642850672","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642850672?lang=en_us&edition=fundamental","pubTime":"2026-06-11 18:31","pubTimestamp":1781173891,"startTime":"0","endTime":"0","summary":"BTIG initiated coverage of Sensei Biotherapeutics (SNSE) with a Buy rating and $55 price target The clinical-stage biotech company is advancing PIK...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sensei-biotherapeutics-initiated-with-a-buy-at-btig-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sensei-biotherapeutics-initiated-with-a-buy-at-btig-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PIK","SNSE","BK4094","BK4139","BK4122","FTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642285483","title":"Sensei Biotherapeutics Initiated at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2642285483","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642285483?lang=en_us&edition=fundamental","pubTime":"2026-06-11 18:30","pubTimestamp":1781173800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SNSE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 11, 2026 06:30 ET (10:30 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FTH","SNSE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642471334","title":"Sensei Biotherapeutics Overhauls Capital Structure at 2026 Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2642471334","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642471334?lang=en_us&edition=fundamental","pubTime":"2026-06-11 05:45","pubTimestamp":1781127949,"startTime":"0","endTime":"0","summary":"The latest update is out from Sensei Biotherapeutics ( ($SNSE) ). On June 10, 2026, Sensei Biotherapeutics held its 2026 annual meeting of stockhol...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sensei-biotherapeutics-overhauls-capital-structure-at-2026-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sensei-biotherapeutics-overhauls-capital-structure-at-2026-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SNSE","FTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642947506","title":"Sensei Biotherapeutics shareholders approve increase in authorized common shares to 300,000,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2642947506","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642947506?lang=en_us&edition=fundamental","pubTime":"2026-06-11 04:21","pubTimestamp":1781122907,"startTime":"0","endTime":"0","summary":"Sensei Biotherapeutics held its annual shareholder meeting on June 10, 2026.Shareholders authorized an increase in common stock authorized shares to 300,000,000 from 12,500,000; the charter amendment took effect June 10, 2026.Shareholders cleared issuance of common stock upon conversion of Series B Non-Voting Convertible Preferred Stock; conversion issuance was not reported as completed.Shareholders adopted the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan; plan implementation actions were not reported as completed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sensei Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retri","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nNDL9cRwHZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FTH","BK4139","SNSE"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":4,"totalSize":75,"code":"91000000","status":"200"}]}}